Article
Gastroenterology & Hepatology
Motohiro Esaki, Yutaro Ihara, Naoyuki Tominaga, Hironobu Takedomi, Nanae Tsuruoka, Takashi Akutagawa, Takahiro Yukimoto, Keisuke Kawasaki, Junji Umeno, Takehiro Torisu, Yasuhisa Sakata
Summary: The therapeutic efficacy of ustekinumab was evaluated in patients with refractory Crohn's disease. It was found that a shorter disease duration and higher baseline serum albumin levels were predictive of a more favorable therapeutic response to ustekinumab. Conversely, higher serum CRP levels were associated with a lower induction efficacy.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE
(2023)
Article
Medicine, General & Internal
Jiayin Yao, Heng Zhang, Tao Su, Xiang Peng, Junzhang Zhao, Tao Liu, Wei Wang, Pinjin Hu, Min Zhi, Min Zhang
Summary: There is insufficient evidence to confirm the efficacy of ustekinumab (UST) in promoting fistula closure in perianal fistulizing Crohn's disease (CD) patients. However, a real-world study found that UST can promote fistula closure and the efficacy is correlated with increased UST trough concentration.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Gastroenterology & Hepatology
Hadrien Alric, Aurelien Amiot, Julien Kirchgesner, Xavier Treton, Mathieu Allez, Yoram Bouhnik, Laurent Beaugerie, Franck Carbonnel, Antoine Meyer
Summary: The VDZ-CDST can predict clinical remission and SFCR at week 48 for vedolizumab, but not for ustekinumab, in CD patients refractory or intolerant to anti-TNF therapy.
INFLAMMATORY BOWEL DISEASES
(2022)
Article
Gastroenterology & Hepatology
Neeraj Narula, Emily C. L. Wong, Parambir S. Dulai, Neil K. Sengupta, John K. Marshall, Jean-Frederic Colombel, Walter Reinisch
Summary: This post hoc analysis suggests that infliximab and ustekinumab have similar efficacy and speed of onset in biologic-naive patients with CD.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2022)
Article
Gastroenterology & Hepatology
N. Hammoudi, J. Lehmann-Che, J. Lambert, M. Amoyel, L. Maggiori, D. Salfati, M. L. Tran Minh, C. Baudry, N. Asesio, B. Poirot, N. Lourenco, H. Corte, M. Allez, T. Aparicio, J. M. Gornet
Summary: This retrospective study in France investigated the prognosis of CRC-IBD and found a relatively low rate of CRC in IBD patients (0.8%) with a median delay of 19.5 years. The overall survival (OS) of the cohort was 45 months, and the OS of metastatic patients was only 20.4 months. Previous exposure to immunosuppressants may be associated with a better prognosis.
DIGESTIVE AND LIVER DISEASE
(2023)
Article
Medicine, General & Internal
Jiayin Yao, Xiang Peng, Yingkui Zhong, Tao Su, Adam Bihi, Junzhang Zhao, Tao Liu, Wei Wang, Pinjin Hu, Min Zhang, Min Zhi
Summary: This study evaluated the efficacy and safety of weight-based UST intravenous reinduction in patients with refractory Crohn's disease. The results showed favorable clinical and endoscopic remission, indicating the prioritization of intravenous reinduction therapy.
FRONTIERS IN MEDICINE
(2023)
Article
Gastroenterology & Hepatology
William J. Sandborn, Rory Rebuck, Yuhua Wang, Bin Zou, Omoniyi J. Adedokun, Christopher Gasink, Bruce E. Sands, Stephen B. Hanauer, Stephan Targan, Subrata Ghosh, Willem J. S. de Villiers, Jean-Frederic Colombel, Brian G. Feagan, John P. Lynch
Summary: The IM-UNITI study and long-term extension (LTE) showed that subcutaneous ustekinumab maintenance therapy had long-term efficacy and safety in patients with Crohn's disease, with significant clinical remission rates observed at 5 years. No new safety signals were found.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2022)
Article
Gastroenterology & Hepatology
David A. Schwartz, Laurent Peyrin-Biroulet, Karen Lasch, Shashi Adsul, Silvio Danese
Summary: This study demonstrated that vedolizumab could significantly improve symptoms and quality of life in patients with fistulizing Crohn's disease, with positive effects on scar tissue formation in particular. Additionally, the addition of an extra dose at week 10 did not affect treatment outcomes. No new safety concerns were identified.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2022)
Article
Gastroenterology & Hepatology
Mohamed A. Abd El Aziz, Solafah Abdalla, Giacomo Calini, Hamadelneel Saeed, Anne-Lise D'Angelo, Kevin T. Behm, Sherief Shawki, Kellie L. Mathis, David W. Larson
Summary: This study retrospectively analyzed the safety of robotic redo ileocolonic resection in 98 patients with Crohn's disease. Patients who underwent redo ileocolonic resection had longer disease duration, more associated anoperineal disease, more previous lines of medical treatments, more frequent use of total parental nutrition before surgery for malnutrition correction, and longer adhesiolysis time. The risk of conversion to open ileocolonic resection was higher in the redo group. There were no significant differences in length of stay and 30-day morbidity between the two groups. No mortality or anastomotic leaks occurred in either group.
DISEASES OF THE COLON & RECTUM
(2023)
Article
Medicine, General & Internal
Naomi Fliss-Isakov, Nathaniel Aviv Cohen, Ahuva Bromberg, Gal Elbert, Ronit Anbar, Yulia Ron, Ayal Hirsch, Tamar Thurm, Nitsan Maharshak
Summary: In this retrospective cohort study, the Crohn's Disease exclusion diet (CDED) was found to induce remission in pediatric and adult patients with CD. The study analyzed the real-world experience of using CDED at the inflammatory bowel disease unit of Tel Aviv Medical Center. The results showed that high adherence to CDED was associated with clinical remission at week 12.
JOURNAL OF CLINICAL MEDICINE
(2023)
Review
Gastroenterology & Hepatology
Mohamed Attauabi, Johan Burisch, Jakob Benedict Seidelin
Summary: In this systematic review with meta-analysis, ustekinumab showed efficacy in treating fistulas in perianal Crohn's disease (pCD), suggesting potential benefits for these patients.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
(2021)
Article
Gastroenterology & Hepatology
Elena Fradkov, Jessica Sheehan, Kelly Cushing, Peter D. R. Higgins
Summary: Concurrent autoimmune skin disease in Crohn's disease is associated with greater effectiveness of ustekinumab in controlling intestinal inflammation. Patients with CD-ASD showed better outcomes in various disease activity markers compared to those without autoimmune skin disease.
INFLAMMATORY BOWEL DISEASES
(2022)
Article
Gastroenterology & Hepatology
Hojjatollah Nazari, Foroogh Alborzi, Asieh Heirani-Tabasi, Alireza Hadizadeh, Reza Akbari Asbagh, Behnam Behboudi, Mohammad Sadegh Fazeli, Mojgan Rahimi, Mohammad Reza Keramati, Amir Keshvari, Alireza Kazemeini, Masoud Soleimani, Seyed Mohsen Ahmadi Tafti
Summary: The injection of exosomes extracted from MSCs for refractory fistulas showed safety and satisfactory therapeutic effects, demonstrating its potential in future treatments of gastrointestinal fistulas.
GASTROENTEROLOGY REPORT
(2022)
Article
Pharmacology & Pharmacy
Marleen Bouhuys, Paola Mian, Patrick F. van Rheenen
Summary: Ustekinumab shows efficacy in pediatric Crohn's disease, but there is limited research on dosing, target trough levels, and therapeutic drug monitoring. Gradually escalating the dose may improve the response to ustekinumab. Further studies are needed to determine the long-term efficacy and optimal trough levels in children.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Gastroenterology & Hepatology
Emily C. L. Wong, Parambir S. Dulai, John K. Marshall, Vipul Jairath, Walter Reinisch, Neeraj Narula
Summary: In this post hoc analysis, treatment with infliximab and ustekinumab achieved 1-year clinical remission with similar efficacy among biologic-naive Crohn's disease patients who responded to induction therapy. However, infliximab may confer greater benefit for endoscopic outcomes.
INFLAMMATORY BOWEL DISEASES
(2023)